[Clinical and hemodynamic effects of anaprilin and carvedilol in patients with coronary heart disease].
50 patients with postinfarction cardiosclerosis and angina pectoris (functional class I-IV) having left ventricular ejection fraction < 45% entered a comparative cross-over trial of antianginal effectiveness of anaprilin and carvediolol (dilatrend). In 10 patients carvedilol was compared to placebo. Carvedilol is shown to demonstrate higher antianginal activity which is the highest in patients with angina pectoris of low load. The analysis of peripheral vascular resistance and double product attributes antianginal advantages of carvedilol to its more potent effect on cardiac performance due to peripheral vasodilatation.